InvestSMART

ChemGenex Pharmaceuticals Ltd (ASX: CXS) - Announcements

DELISTED - Current share price for CXS : $0.700

ASX company news and announcements for ChemGenex Pharmaceuticals Ltd (CXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ChemGenex Pharmaceuticals Ltd (CXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ChemGenex Pharmaceuticals Ltd (CXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ChemGenex Pharmaceuticals Ltd (CXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Placement 17 Sep 2008 10:00AM $0.795 $0.700 fallen by 11.95%
- Trading Halt 12 Sep 2008 5:24PM $0.810 $0.700 fallen by 13.58%
- Preliminary Final Report 29 Aug 2008 5:01PM $0.760 $0.700 fallen by 7.89%
- Response to ASX Price Query 23 Jul 2008 9:24AM $1.150 $0.700 fallen by 39.13%
- Initiates Rolling NDA Submission for Omacetaxine 1 Jul 2008 9:30AM $1.200 $0.700 fallen by 41.67%
- Data from Clinical Investigators at EHA Congress 16 Jun 2008 9:33AM $1.000 $0.700 fallen by 30%
- ChemGenex Acquires Full Control of Omacetaxine 10 Jun 2008 9:10AM $1.005 $0.700 fallen by 30.35%
- Updated clinical data on omacetaxine presented at conference 3 Jun 2008 9:33AM $0.930 $0.700 fallen by 24.73%
- Updates Omacetaxine Mechanism at International Conference 15 Apr 2008 8:31AM $0.870 $0.700 fallen by 19.54%
- Confirms NDA Rolling Submission after meeting with FDA 14 Apr 2008 10:05AM $0.870 $0.700 fallen by 19.54%
- Clinical trial data presented at international conference 1 Apr 2008 9:41AM $0.850 $0.700 fallen by 17.65%
- Initiates phase 2 clinical trial of omacetaxine in AML 11 Mar 2008 9:40AM $0.730 $0.700 fallen by 4.11%
- Half Yearly Report and Accounts 27 Feb 2008 5:23PM $0.730 $0.700 fallen by 4.11%
- Omacetaxine Effective in Killing Leukemic Stem Cells 11 Dec 2007 9:37AM $1.080 $0.700 fallen by 35.19%
- Clinical Activity of Omacetaxine Reported at Conference 10 Dec 2007 9:26AM $1.080 $0.700 fallen by 35.19%
- Strategic Restructuring to Focus Company on Cancer Assets 29 Oct 2007 9:26AM $1.120 $0.700 fallen by 37.50%
- Positive clinical data on Ceflatonin presented at conference 1 Oct 2007 9:37AM $1.010 $0.700 fallen by 30.69%
- Preliminary Final Report 31 Aug 2007 11:59AM $1.010 $0.700 fallen by 30.69%
- Ceflatonin Clinical Activity in T315I-Positive CML Confirmed 12 Jun 2007 9:40AM $0.985 $0.700 fallen by 28.93%
- Quinamed Clinical Success Reported at ASCO 5 Jun 2007 9:30AM $0.960 $0.700 fallen by 27.08%
- Initiation of second phase 2/3 clinical trial for Ceflatonin 4 Apr 2007 9:41AM $0.830 $0.700 fallen by 15.66%
- 1 for 10 Rights Issue Prospectus 26 Feb 2007 9:25AM $0.729 $0.700 fallen by 3.91%
- Half Yearly Report/Half Year Accounts 23 Feb 2007 1:27PM $0.719 $0.700 fallen by 2.60%
- New Investors/Capital Raising/Rights Issue/Board Changes 8 Feb 2007 5:27PM $0.680 $0.700 risen by 3%
- Granted US Patent for Ceflatonin Manufacturing 2 Feb 2007 10:04AM $0.616 $0.700 risen by 13.64%

51 - 75 of 105 results

Page 3 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.